Skip to Main content Skip to Navigation
Journal articles

Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells

Sandrine Valsesia-Wittmann 1 Beatrice Clemenceau 2 Anne-Catherine Jallas 1 Jean-Yves Blay 1 Aurelien Marabelle 1 Christophe Caux 1 Henri Vie 2
1 P3I - Innovation en Immonomonitoring et Immunothérapie
2 CRCNA - Centre de Recherche en Cancérologie Nantes-Angers
Document type :
Journal articles
Complete list of metadatas
https://www.hal.inserm.fr/inserm-00881032
Contributor : Ed. Bmc <>
Submitted on : Thursday, November 7, 2013 - 1:04:54 PM
Last modification on : Wednesday, September 16, 2020 - 1:06:04 PM
Long-term archiving on: : Saturday, February 8, 2014 - 7:05:09 AM

Files

Vignette du document
2051-1426-1-S1-P176.pdf
Publisher files allowed on an open archive

Identifiers

  • HAL Id : inserm-00881032, version 1

Collections

CNRS | UNAM

Citation

Sandrine Valsesia-Wittmann, Beatrice Clemenceau, Anne-Catherine Jallas, Jean-Yves Blay, Aurelien Marabelle, et al.. Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells. Journal for Immunotherapy of Cancer, BMJ Publishing Group 2013, 1 (Suppl 1), pp.P176. ⟨inserm-00881032⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

487

Files downloads

493